The use of tricyclic antidepressants in the treatment of temporomandibular joint disorders: systematic review of the literature of the last 20 years by Cascos-Romero, Jordi et al.
E3
Med Oral Patol Oral Cir Bucal. 2009 Jan 1;14 (1):E3-7.                                                                                                                                                        Tricyclic antidepressants and joint pathology                                                                           Med Oral Patol Oral Cir Bucal.  2009 Jan 1;14 (1):E3-7.                                                                                                                                                        Tricyclic antidepressants and joint pathology 
The use of tricyclic antidepressants in the treatment of temporomandibular joint 
disorders: Systematic review of the literature of the last 20 years
Jordi Cascos-Romero 1, Eduardo Vázquez-Delgado 2, Eduardo Vázquez-Rodríguez 3, Cosme Gay-Escoda 1 
(1) Collaborating Professor of the Oral Surgery and Implantology Master Degree Program. College of Dentistry of the University of Bar-
celona, Spain
(2) Chief Professor of the TMJ and Orofacial Pain Unit of the Oral Surgery and Implantology Master Degree Program. College of Den-
tistry of the University of Barcelona, Spain. Orofacial Pain Specialist of the TMJ and Orofacial Pain Unit of the Teknon Medical Center, 
Barcelona, Spain
(3) Associate Professor of the Oral Surgery and Implantology Master Degree Program. College of Dentistry of the University of Barcelona, 
Spain. Co-Director of the TMJ and Orofacial Pain Unit of the Teknon Medical Center, Barcelona, Spain
(4) Chairman of the Oral Surgery Department and Director of the Oral Surgery and Implantology Master Degree Program. College of Den-
tistry of the University of Barcelona, Spain. Chairman of the Oral, Maxillofacial,and Implantological Surgery Department and Co-Director 
of the TMJ and Orofacial Pain Unit of the Teknon Medical Center, Barcelona, Spain
Correspondence:
Prof. Cosme Gay Escoda
Centro Médico Teknon
C/ Vilana nº 12
08022 Barcelona. Spain
cgay@ub.edu
Received: 25/01/2007
Accepted: 02/11/2008
Cascos-Romero J, Vázquez-Delgado E, Vázquez-Rodríguez E, Gay-Escoda 
C. The use of tricyclic antidepressants in the treatment of temporomandibular 
joint disorders: Systematic review of the literature of the last 20 years. Med 
Oral Patol Oral Cir Bucal. 2009 Jan 1;14 (1):E3-7.
© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946
http://www.medicinaoral.com/medoralfree01/v14i1/medoralv14i1p3.pdf
Abstract
Many therapies have been proposed for the management of temporomandibular disorders, including the use of different 
drugs. However, lack of knowledge about the mechanisms behind the pain associated with this pathology, and the fact that 
the studies carried out so far use highly disparate patient selection criteria, mean that results on the effectiveness of the di-
fferent medications are inconclusive. This study makes a systematic review of the literature published on the use of tricyclic 
antidepressants for the treatment of temporomandibular disorders, using the SORT criteria (Strength of recommendation 
taxonomy) to consider the level of scientific evidence of the different studies. Following analysis of the articles, and in 
function of their scientific quality, a type B recommendation is given in favor of the use of tricyclic antidepressants for the 
treatment of temporomandibular disorders. 
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Introduction
Temporomandibular disorders (TMDs) is a collective term 
that includes disorders of the temporomandibular joint (TMJ), 
and of the masticatory muscles and their associated structures; 
characterized by pain, joint sounds, and restricted mandibular 
movement (1). Among other signs and symptoms, headaches 
and sleep disturbances can appear concomitantly (2). 
The pathogenesis of the pain in TMDs remains unclear. 
Numerous factors, both physical, as well as biochemical and 
physiological have been related to the origin and evolution of 
this pathology; thus numerous types of treatment have been 
proposed in the literature, although with highly disparate 
results among the published studies (3-5).
Regarding pharmacologic therapy, the effects of nonsteroidal 
anti-inflammatory drugs (NSAIDs), corticosteroids, muscle 
relaxants, anxiolytics, opioids and tricyclic antidepressants 
(TCAs) on TMDs have been studied among others, although 
with no conclusive results for any medication. However, in 
those cases where a TMD is associated with states of anxie-
ty, depression and/or stress, the use of drugs may be clearly 
indicated (3,5-7). Other agents such as capsaicin in topical 
application or hyaluronic acid by intraarticular injection have 
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also been studied, although there is insufficient scientific 
evidence to corroborate their effectiveness in treating TMDs 
(3,7,8). 
Tricyclic antidepressants are the most studied regarding 
indication in the management and control of chronic pain in 
the orofacial area, as in the case of diverse musculoskeletal 
dysfunctions (myofascial pain and fibromyalgia) and other 
clinical entities such as primary headaches (migraine, tension 
type headaches, etc.), or certain neuropathies (diabetic neuro-
pathy, atypical odontalgia, postherpetic neuralgia, traumatic 
trigeminal neuralgia, etc.) (9,10).
The aim of this article is to make a systematic review of the 
literature published on the use of TCAs for the treatment of 
TMDs in the last 20 years, considering their level of scien-
tific evidence according to the principals of evidence-based 
dentistry.
Material and Methods
A MEDLINE search was made for articles published bet-
ween the years 1988 and 2008. The MeSH (Medical Subject 
Heading) keywords and headings were used for "TMDs" to 
obtain a core bank of articles on this pathology. The literature 
identified was then limited to studies in humans and articles 
written in English. A similar search was made for "TRICY-
CLIC ANTIDEPRESSANTS." Both search strategies were in 
turn merged by means of the Boolean operator "AND", thus 
linking the articles on TMDs and TCAs. The same process 
was used in the COCHRANE database of the Cochrane Oral 
Health Group. Two authors analyzed the abstracts to verify 
that the articles obtained were pertinent to the topic under 
study. The irrelevant articles were discarded. Next, the same 
two authors independently stratified the scientific articles 
according to their level of scientific evidence using the SORT 
criteria (Strength of Recommendation Taxonomy) (11). 
Subsequently the authors compared their results; in the event 
of disagreement the results were discussed. If no consensus 
regarding the level of scientific evidence of a certain article 
was possible, a third author was included in the discussion. 
Subsequently, a recommendation was given for or against the 
use of this medication in the treatment of TMD according to 
the level of scientific evidence of the articles analyzed.
Results
The MEDLINE search for TMDs provided a bank of 8,900 
articles. The search for tricyclic antidepressants provided 
19,571 articles. As previously mentioned, both searches were 
then cross-referenced. This provided a bank of 67 articles. 
Next, the abstracts of each article were analyzed to determine 
if they were pertinent to the topic under study. The search 
in the COCHRANE database provided no relevant articles 
that agreed with the search criteria of this study. After this 
process 11 relevant articles remained. These articles were 
critically analyzed and classified according to their level of 
scientific evidence. 
This analysis produced 7 literature review articles, an article 
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presenting a clinical case (level 3), 1 study of treatment effec-
tiveness (level 3), a double blind study with a small sample 
of patients (level 2), and a low quality (level 2) meta-analysis 
that included all the clinical studies in the literature on TCAs 
in the treatment of TMD.
Description of studies.
1. Pettengill CA, Reisner-Keller L (10).
Literature review. Evidence level 3.
2. Reisner-Keller L (12).
Literature review. Evidence level 3.
3. Dionne RA (13).
Literature review. Evidence level 3.
4. Tversky J, Reade PC, Gerschman JA, Holwill BJ, Wright 
J (14).
Case control study. Evidence level 2.
5. Harris M, Feinmann C, Wise M, Treasure F (15).
Literature review. Evidence level 3.
6. Denucci D, Dionne R, Dubner R (16).
Literature review. Evidence level 3.
7. Barker E, Blakely R (17).
Literature review. Evidence level 3.
8. Haas D (8).
Literature review. Evidence level 3.
9. Rizzatti-Barbosa CM, Nogueira MTP, de Andrade ED, 
Ambrosano CMB, de Barbosa JR (9).
Double blind clinical study (small patient sample and incon-
sistent results). Evidence level 2.
10. Plesh O, Curtis D, Levine J, McCall WD (18).
Pilot study on efficacy of treatment. Evidence level 3.
11. List T, Axelsson S, Leijon G (19).
Systematic literature review. Evidence level 2.
The results of studies with evidence level 2 are summarized 
in Table 1 (the literature reviews are excluded).
In accordance with the principals of evidence-based dentistry, 
the analysis produced a level B recommendation in favor of 
using TCAs in the treatment of TMDs. However, this result 
should be taken most cautiously since this recommendation 
is based on the only controlled study published so far, and 
which presents important methodological defects such as 
insufficient sample size and/or lack of homogeneity among 
the studied populations among others.
Discussion
Diverse signs and symptoms can be found in TMD, of which 
pain and joint dysfunction are the most frequent clinical fin-
dings (3,4,10,15,20). The chronic pain associated with TMDs 
is treated with peripheral analgesics (mainly NSAIDs), mus-
cle relaxants, opioids and benzodiazepines (3,10,11,18). More 
recently TCAs, specifically amitriptyline, have been added 
to the therapeutic arsenal (14). Since the 1960s, TCAs have 
been accepted for the treatment of chronic pain syndromes 
(3,19,21,22). In this regard, Onghena and Houdenhove (23) 
demonstrated their efficacy in chronic pain in a metaanalysis 
that compiled 39 quality scientific studies (controlled clinical 
studies with placebo).
Publications are scarce on the specific case of using TCAs 
in TMDs. Our search found only 11 studies that fulfilled our 
criteria, most being literature reviews based on studies of 
the efficacy of these antidepressant medications, specifically 
amitriptyline, for the control of chronic pain of other origins 
such as diabetic or postherpetic neuropathies and primary 
headaches, among others.
For most authors (9,15,24), the analgesic effect of TCAs is 
due to the serotonin and noradrenaline reuptake inhibition 
at synaptic level in the central nervous system (CNS). The 
blocking of these two amines increases their concentration 
and availability in the synaptic space of the nerve endings in 
the posterior horn of the spinal cord (involved in the trans-
mission of pain) favoring or prolonging the inhibitory action 
in the transmission of this pain (10,23).
Nevertheless, this would only provide a partial explanation 
of the action mechanism by which TCAs produce an effect 
in the management of chronic pain. Other theories have been 
proposed that suggest that an interaction of TCAs would exist 
with the endogenous opioids and the spinal adrenergic system, 
although the specific physiologic bases of this interaction are 
unknown (25).
It has also been suggested that since most patients who suffer 
chronic pain usually have associated depressive states, in 
many cases related with some type of disturbance in sleep 
patterns, the pain could be indirectly decreased due to the 
change in these patterns, especially in those patients with a 
depletion in serotonin levels in the CNS (9,10). The study 
by Tversky et al. (14) which indicates that depressive states 
play a crucial role in the therapeutic response of patients 
with TMDs would confirm this hypothesis, since chronic 
pain leads to mood changes in the patient, and therefore an 
evaluation of the psychological status before any treatment 
planning would be mandatory. However, the specific phy-
siologic bases of the mechanism by which TCAs provide an 
analgesic effect are unknown (10).
According to some authors (8,10), the use of TCAs in patients 
with TMDs, besides being effective in the control of pain, 
reduces the number of sleep disturbances, extending stage IV 
or delta sleep, and considerably reducing REM sleep. They 
are effective in the treatment of the night bruxism associa-
ted with these sleep disturbances and, due to the sedative 
action, would induce a muscle relaxing action at central 
level. Therefore, according to these authors, their use would 
be indicated when other treatments (splints, physiotherapy, 
etc.) have been ineffective (10) or they can be administered 
simultaneously (18). However, no scientific study exists that 
demonstrates the efficacy of these medicines in any of the 
above-mentioned cases.
The doses of TCAs used for pain management are usually 
much lower (10 to 20 times) than those used to control de-
pression (8). For the specific case of amitriptyline, which 
continues to be the most used TCA in the management of 
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pain associated with TMDs, the recommended posology 
varies between 25 and 150 mg daily, proposed by Pettengill 
and Reisner-Keller (10) and Kreisberg (24). The treatment 
begins at a low dose (between 10 and 25 mg day) increasing 
gradually until obtaining a considerable decrease or the total 
disappearance of the patient’s symptoms (10,13,22,24). In 
this regard, Plesh et al. (18) carried out a pilot study in 25 
patients investigating the efficacy of amitriptyline at low 
doses (between 10 and 30 mg) in reducing pain in 2 groups 
of patients with chronic temporomandibular pain (myofascial 
pain and arthralgias). From the results obtained they conclu-
ded that amitriptyline in low doses is effective in reducing 
pain. However, they found that the pain reduction is better at 
6 weeks than one year after commencing therapy, especially 
in the myofascial pain group, although they do not justify 
this fact.
Rizzatti-Barbosa et al. (9) published a double-blind study 
in which they sought to verify the efficacy of amitriptyline 
in chronic pain management in TMD on a sample of 12 
women medicated over 14 days. The authors concluded 
that amitriptyline at a dosage of 25 mg / day is effective in 
reducing pain and discomfort in chronic temporomandibular 
pain. However, no greater analgesic effect is obtained when 
using amitriptyline in higher concentrations (50-75 mg / day), 
although the side effects are greater. 
Studies by Sharav et al. (26) and McQuay et al. (27,28) 
obtained similar results to those of the above, but should be 
considered with caution since the sample size is inadequate 
and there are numerous methodological errors.
In contrast to these conclusions, Dionne (13) suggests that 
the analgesic effect of amitriptyline is no higher than with a 
placebo, attributing this to the psychogenic factor present in 
many cases and to the difficulty for the patient to measure 
subjective sensations of pain and discomfort. On the other 
hand, Zitman et al. (29) indicate that an improvement in the 
symptoms exists, but is smaller than expected. 
None of the studies found in the literature can be classified 
as scientific evidence level 1 according to the SORT crite-
ria. The best quality scientific study found in the literature 
corresponds to a systematic review which aimed to analyze 
the randomized clinical studies published in the MEDLINE, 
Cochrane Library, EMBASE and Psych Litt databases to de-
termine the efficacy and the safety of the drug therapies used 
in the treatment of TMDs (they included rheumatoid arthritis 
and burning mouth syndrome) (19). The authors found 11 
studies that included 368 patients in total. The effectiveness 
in the management of pain in TCAs was demonstrated in 
only one of the studies. These authors concluded that there 
is no scientific evidence to demonstrate the efficacy of any 
drug in the control of TMDs, and therefore more randomized 
controlled studies would be necessary to obtain consistent 
results for each of the therapies. The above study cannot be 
considered as level 1 of the SORT criteria because limitations 
in the selection criteria prevent it from being considered a 
metaanalysis.
Conclusions
Publications on the use of TCAs for the treatment of TMDs 
are scarce, most are literature reviews that extrapolate the 
results obtained with these drugs in other chronic pain patho-
logies in different areas of the body to pain in the orofacial 
area.
According to the principals of evidence-based dentistry, there 
is currently a scientific evidence level B in favor of using 
TCAs for the treatment of TMDs. No studies on this topic 
exist that fulfill the conditions for classification as scientific 
evidence level 1 according to SORT criteria. This means 
that the results published in the literature should be analy-
zed with caution since none have sufficient scientific basis, 
either because the sample size is inadequate, methodological 
defects are present, for example the lack of homogeneity of 
the populations studied, or, as commented above, because 
the results are extrapolated.
There are no scientifically sound studies that demonstrate the 
effectiveness of TCAs in the treatment of TMDs, therefore, 
more controlled clinical trials are necessary to demonstrate 
this hypothetical efficacy, and to assess the dose required for 
each pathology type and its associated side effects, among 
other parameters. 
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